Literature DB >> 22591071

Prognosis in primary effusion lymphoma is associated with the number of body cavities involved.

Jorge J Castillo1, Helen Shum, Majid Lahijani, Eric S Winer, James N Butera.   

Abstract

Primary effusion lymphoma (PEL) is a rare lymphoma associated with Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), and characterized by a malignant body cavity effusion without solid organ or nodal involvement. Prognostic factors in patients with PEL have not been systematically studied. We conducted a literature search for patients with HHV8-positive PEL to identify potential prognostic factors for survival. Our search identified 147 patients, among which 104 patients were HHV8-positive. The median overall survival was 9 months. The median age was 57 years with a male predominance (6:1). Pathologically, 33% of the patients expressed CD20 and 69% expressed CD30. Patients with PEL with > 1 body cavity involved had a median overall survival (OS) of 4 months compared with 18 months in patients with only one cavity involved (p = 0.003). Additionally, in patients with one involved body cavity, pericardial involvement was associated with a longer median OS than pleural followed by peritoneal involvement (40, 27 and 5 months, respectively; p = 0.04). In conclusion, our study suggests that the number and location of body cavities involved are prognostic in patients with PEL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22591071     DOI: 10.3109/10428194.2012.694075

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  17 in total

Review 1.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

2.  HIV-associated primary effusion lymphoma presenting as a paracardial mass.

Authors:  Heather Katz; Cielo Rose; Nina Thakker Rivera; Natasha Bray
Journal:  BMJ Case Rep       Date:  2015-02-27

3.  Sustained complete remission of primary effusion lymphoma with adjunctive ganciclovir treatment in an HIV-positive patient.

Authors:  Rui Pereira; Joana Carvalho; Catarina Patrício; Pedro Farinha
Journal:  BMJ Case Rep       Date:  2014-10-13

Review 4.  Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.

Authors:  William R Foster; Alina Bischin; Russell Dorer; David M Aboulafia
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-04-01

5.  Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.

Authors:  Jutatip Panaampon; Ryusho Kariya; Seiji Okada
Journal:  Cancer Immunol Immunother       Date:  2022-03-09       Impact factor: 6.630

Review 6.  Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.

Authors:  C Evangelisti; C Evangelisti; F Buontempo; A Lonetti; E Orsini; F Chiarini; J T Barata; S Pyne; N J Pyne; A M Martelli
Journal:  Leukemia       Date:  2016-07-27       Impact factor: 11.528

Review 7.  CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.

Authors:  Jing Li; Shu Zhao; Jingxuan Wang; Jingyu Chen; Wen Wen; Qingyuan Zhang
Journal:  Tumour Biol       Date:  2015-10-12

8.  Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma.

Authors:  Hiroki Goto; Eriko Kudo; Ryusho Kariya; Manabu Taura; Harutaka Katano; Seiji Okada
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-11       Impact factor: 4.553

Review 9.  KSHV/HHV8-mediated hematologic diseases.

Authors:  Ethel Cesarman; Amy Chadburn; Paul G Rubinstein
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

10.  Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone.

Authors:  Junghoon Shin; Jeong-Ok Lee; Ji-Young Choe; Soo-Mee Bang; Jong-Seok Lee
Journal:  Cancer Res Treat       Date:  2016-06-10       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.